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We identified 306 invasive group A streptococcal infec-
tions (IGASI) by passive population-based surveillance in
Montreal, Canada, from 1995 to 2001. The average yearly
reported incidence was 2.4 per 100,000 persons, with a
14% death rate. Among clinical manifestations, incidence
of pneumonia increased from 0.06 per 100,000 in 1995 to
0.50 per 100,000 in 2000. Over a span of 7 years, the odds
of developing pneumonia increased (odds ratio [OR] =
1.21, 95% confidence interval [CI] 1.0–1.5), while they
decreased for soft-tissue infections (OR = 0.86, 95% CI
0.7–1.0). Serotypes M1 and M3 accounted for 30% of
IGASI. However, neither serotype was significantly associ-
ated with specific clinical manifestations, which suggests
that manifestation development among IGASI might be
attributable to host or environmental factors rather than the
pathogen. In our study, these factors included age, gender,
underlying medical conditions, and living environment, yet
none explained temporal changes in risk for pneumonia
and soft-tissue infections. 
S
ince the mid-1980s, concern has grown that invasive
group A streptococcal infections (IGASI) have been
increasing in incidence and severity (1–3). In particular,
the emergence of streptococcal toxic shock syndrome
(STSS) during the 1980s is frequently cited as an example
of increasing severity (4). 
Person-to-person transmission of Streptococcus pyo-
genes (the causative agent for IGASI) primarily occurs
through respiratory droplets, although it may also spread
through body secretions from an infected patient (5,6).
Additionally, M serotypes of S. pyogenes that cause severe
disease in a patient are more likely to cause severe disease
in subsequent patients (6). These serotypes include 3 (M1,
M3, and M18) that are strongly associated with patho-
genicity (7). Nonetheless, some evidence indicates that
persons with IGASI from the same strain of S. pyogenes
may have different clinical manifestations of this disease
(8,9). Other risk factors for IGASI include patient’s age
and underlying medical conditions (e.g., varicella).
However, what factors may be associated with different
clinical manifestations of IGASI is unclear (10–22). 
Some studies have examined the role of age, varicella,
and chronic conditions such as diabetes mellitus and alco-
holism as predictors for necrotizing fasciitis, soft-tissue
infections, and STSS (21–24), yet little is known regarding
other IGASI determinants. In this study, we describe the
status of both IGASI and their clinical manifestations on
the island of Montreal. We also identify predictors for clin-
ical manifestations and death due to IGASI, which could
explain temporal fluctuations in the incidence and severity
of this disease. 
Methods
Surveillance of IGASI
Data used in our study were collected during passive
surveillance of IGASI among all residents of the island of
Montreal (population = 1.8 million: 21,529 births per year
from 1996 to 1999 [25]). Cases that occurred and were
reported from January 1, 1995 (the year IGASI became a
notifiable disease in the province of Quebec), through
February 28, 2002, were included in our study. 
Once the public health department had been notified of
a potential case, usually by a hospital laboratory, a 6-part
questionnaire was completed by using information from
the physician or infection control nurse of the health
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Questions included the patient’s demographic information,
general medical information, laboratory results, diagnostic
criteria, and medical history before the IGASI. With this
information, all IGASI were classified into 1 of 3 groups:
confirmed cases (S. pyogenes isolated from a normally
sterile site), clinical cases (S. pyogenes isolated from a
nonsterile site and toxic shock not attributable to any other
cause), or noncases. Data on confirmed and clinical cases
were entered into the regional notifiable infections com-
puter database. This database was used for our study. 
Laboratory Assessment of IGASI Isolates
Initial laboratory confirmation of S. pyogenes was
made by using standard methods (26). Isolates were then
collected and sent to the Canadian National Center for
Streptococcus in Edmonton for further testing of the opac-
ity factor, as well as M, T, and R surface proteins. The
methods have been described in detail elsewhere (27).
Briefly, antiopacity factor (AOF) typing was performed on
any positive opacity factor sample. Although AOF testing
does not possess the same type specificity as M typing, it
is frequently used because of difficulties in producing anti-
sera for certain M serotypes. Its use has been validated for
most strains identified in industrialized countries.
However, since 2000, the national center has supplement-
ed AOF testing with emm gene sequencing for some non-
typeable M serotype samples. Data on these results were
not available for this study. 
Classification of Outcomes
For our study, we looked at 5 dichotomous outcomes:
STSS, soft-tissue infections, bacteremia, pneumonia, and
death attributable to IGASI. All were invasive and defined
in accordance with the classification of group A strepto-
coccal infections (28).
STSS was defined according to the 1993 Working
Group on Severe Streptococcal Infections consensus defi-
nition for a probable or confirmed case (28). Soft-tissue
outcomes included fasciitis, myositis, cellulitis, or
erysipelas. Bacteremia was characterized by a positive
hemoculture, without any source of infection. Pneumonia
attributable to IGASI was based on a clinical diagnosis
made by the treating physician and could include STSS
with respiratory distress. 
Classification of Independent Variables
Age, calendar month, and year in which the IGASI case
occurred were included in our study as continuous vari-
ables. Gender (male or female); underlying medical condi-
tions (drug use, alcohol abuse, varicella, prior trauma or
wound, cancer, and immunosuppression); type of living
environment (hospital, daycare or preschool, school, work,
other, and not available); as well as M, T, and R surface
protein serotypes (presence or absence of a specific
serotype) were all included as dichotomous variables. For
those serotypes with identical strength of association with
a given outcome, a single new dichotomous variable was
created to represent the presence of one or the other (e.g.,
presence of either serotype M12 or M28 versus absence of
both serotypes). Finally, since predominant site of infec-
tion (bacteremia, fasciitis, cellulitis or erysipelas, myositis,
peritonitis, respiratory manifestations, septic arthritis, and
other) was partially used in distinguishing between bac-
teremia, pneumonia, and soft-tissue infections, this vari-
able was only considered a covariate of interest in models
with STSS and death as their outcomes. 
Statistical Analysis
The incidence (per 100,000), death rate attributable to
IGASI, and proportion of IGASI cases due to a specific
clinical manifestation were estimated by using data collect-
ed from 1995 through 2001. Incidence and proportion esti-
mates were not calculated for 2002, given that only 2
months of data were available. Projected annual population
estimates for Montreal were used when calculating the
reported annual incidence of IGASI (25). Incidence and
proportion of IGASI cases stratified by gender, calendar
year, and age group were then calculated. Finally, temporal
trends were assessed by using the chi-square test for trend. 
For the inferential component of our study, we con-
ducted unconditional logistic regression with SAS version
8.0 (SAS Institute, Cary, NC, USA). This test was initially
performed by including in the model variables with a uni-
variate likelihood ratio p value <0.20. Among these fac-
tors, those with the highest multivariate Wald chi-square p
value were then individually dropped, until the lowest
Akaike Information Criterion value was attained. The
McGill University Faculty of Medicine Institutional
Review Board approved the study.
Results
From 1995 through 2001, a total of 306 cases of IGASI
were reported on the island of Montreal. The incidence of
IGASI rose from 1.05 per 100,000 (19 cases) in 1995 to
1.71 (31 cases) in 1996 and 3.32 (60 cases) in 1997. After
1997, the incidence appeared to stabilize: 2.77 (50 cases)
in 1998, 2.50 (45 cases) in 1999, 3.21 (58 cases) in 2000,
and 2.37 (43 cases) in 2001. The average annual incidence
of IGASI was 2.4 per 100,000. Most IGASI cases occurred
in persons >40 years of age (172 [56%] of 306 cases)
(Figure 1). The median age of patients was 46 years (range
1.5 months to 92 years). 
Of the 306 reported IGASI cases, 112 (37%) were soft-
tissue infections, 84 (28%) bacteremia, 32 (10%) pneumo-
nia, and 29 (10%) STSS. Among patients with soft-tissue
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cellulitis, and 76 (68%) had necrotizing fasciitis; 1 patient
had both cellulitis and necrotizing fasciitis. We did not
identify any significant trend over time with regard to the
proportion of different clinical manifestations. As for
specific clinical manifestations of IGASI, we estimated
that bacteremia occurred, on average, in 0.66 per 100,000
persons each year, STSS in 0.23 per 100,000, soft-tissue
infections in 0.89 per 100,000, and pneumonia in 0.25 per
100,000. 
The predominant M serotypes included M1 (22%), M3
(12%), M28 (9%), M12 (8%), M4 (6%), and M6 (4%).
Remaining serotypes accounted for <3% of isolates.
Twenty percent of samples were nontypeable.
Pneumonia
The incidence of pneumonia appeared to significantly
increase over time (χ2 = 5.65, p = 0.018), with an annual
incidence of 0.06 per 100,000 in 1995 and 1996, 0.28 in
1997 and 1998, 0.39 in 1999, 0.50 in 2000, and 0.22 in
2001. This finding was confirmed by the odds of having
pneumonia significantly increasing with each successive
calendar year (adjusted odds ratio [aOR] = 1.21, 95% con-
fidence interval [CI] 1.0–1.5). The proportion of women
and girls with pneumonia (Figure 2) also significantly
increased (χ2 = 5.03, p = 0.025), with women more likely
to have pneumonia as compared to men (aOR 2.20, 95%
CI 1.0–4.9). Gender was not associated with year in which
the case occurred. 
STSS
We did not detect a significant secular trend in the
occurrence of STSS (χ2 = 0.54, p = 0.46). Persons who
abused alcohol (aOR 7.66, 95% CI 1.9–30.3), were infect-
ed with serotype M9 (aOR 39.98, 95% CI 1.9–836), or
who had fasciitis (aOR 10.21, 95% CI 4.1–25.7) were at a
significantly greater risk of having STSS. 
Soft-tissue Infections
No significant secular trend was apparent in the inci-
dence of soft-tissue infections (χ2 = 0.48, p = 0.49).
However, the odds of developing this manifestation as
opposed to another significantly decreased with each suc-
cessive calendar year (aOR 0.86, 95% CI 0.7–1.0). Drug
use was weakly associated with soft-tissue infections
(unadjusted OR 1.86, 95% CI 0.8–4.4). Given that trauma
was a significant univariate risk marker for soft-tissue
infections (OR 2.78, 95% CI 1.6–4.8), this association
might have been attributable to injection drug use resulting
in a trauma or wound. However, in our study, no correla-
tion was seen between drug use and trauma (r = 0.002, p =
0.97). Furthermore, the association between drug use and
soft-tissue infections became significant after adjusting for
trauma or wound (OR 2.83, 95% CI 1.0–8.0). 
Varicella and serotypes M6, M12, or M22 were signif-
icant predictors for developing soft-tissue infections with
aORs of 5.69 (95% CI 1.4–23.1), 4.3 (95% CI 1.1–16.7),
9.1 (95% CI 1.3–64.5), and 27.9 (95% CI 2.7–289),
respectively. None of these factors were correlated with
calendar year. 
Bacteremia
The incidence of bacteremia did not appear to change
over time (χ2 = 0.56, p = 0.45). Only protective factors
against bacteremia were identified: attending a school
(aOR 0.15, 95% CI 0.0–0.7) and trauma or wound (aOR
0.4, 95% CI 0.2–0.9). 
Death Due to IGASI
The death ratio from IGASI was 15% (42 deaths among
306 cases). The highest proportion of known deaths was
among patients with pneumonia (38%, 12 deaths among
32 pneumonia cases), followed by STSS (35%, 10 among
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Figure 1. Annual incidence and death rate of invasive group A
streptococcal infections, by age, in Montreal, Canada, 1995-2001.
Figure 2. Pneumonia as a proportion of invasive group A strepto-
coccal infections (IGASI) by gender, Montreal, Canada,
1995–2001.29), bacteremia (17%, 14 among 84), and soft-tissue infec-
tions (10%, 11 among 112). Within soft-tissue infections,
necrotizing fasciitis had the highest risk for death among
all age groups (16%, 5 deaths among 31 cases) followed
by cellulitis and erysipelas (8%, 6 among 76). For myosi-
tis, among the 6 cases identified during a 7-year period, no
deaths were recorded. No secular trends for death ratios
were seen for any of the clinical manifestations of IGASI.
Among those who died of IGASI, the most common
serotypes were M1 (34%) and T1 (30%); however, neither
was significantly associated with death (unadjusted OR for
M1: 1.86, 95% CI 0.9–4.0; T1: 1.91, 95% CI 0.9–4.1).
Predictors for death, after adjustment, are presented in the
Table.
Discussion
When the results of our study are examined, several
methodologic considerations must be taken into account.
First, given that the administration of questionnaires for
this study was not standardized, nondifferential misclassi-
fication could explain why certain factors in this study
were not identified as potential markers for clinical mani-
festation outcomes. 
An additional limitation of our study was the low sta-
tistical power. For some measures of association, the prob-
ability of detecting a true association was estimated to be
as low as 3%. As a result, while this study can identify
potential predictors, it cannot exclude them. 
Additionally, given that this study was to a certain
extent hypothesis-generating, some of the predictors found
in this study (particularly those with weak associations)
may have occurred by chance. Considering that an α level
of 0.05 was used when testing ≈200 associations, at least
10 significant factors would be expected to be identified by
chance. In our study, we identified 25 factors to be signif-
icantly associated with specific IGASI manifestations. 
IGASI and STSS may be increasing in both incidence
and severity (4). In particular, increasing trends in the
IGASI incidence in the United States have been recorded
in several hospital-based studies (29). Furthermore, past
European studies noted a general increase in the incidence,
although little evidence shows a trend occurring in the
United States (14,30–32). While we documented a trend in
the annual incidence of IGASI in Montreal during the first
3 years of our study, the incidence stabilized from 1997
onwards, which suggests that an initial rise in incidence
might be attributable to underreporting immediately after
IGASI became a notifiable disease. During the 7 years of
our study, mortality did not appear to significantly change.
Additionally, we could not identify any significant trends
in the incidence and mortality of STSS. We did, however,
ascertain that pneumonia attributable to IGASI significant-
ly increased during 6 of the 7 years of our study. This find-
ing was particularly evident among women. Our findings
agree with those of a study in Ontario, which identified an
increasing trend for pneumonia attributable to GAS from
1992 to 1999 (33). 
To the best of our knowledge, no research has been
published on transmission rates for the different clinical
manifestations of IGASI. However, the primary mode of
person-to-person transmission of S. pyogenes is through
respiratory droplets (5,6). Additionally, S. pyogenes that
causes severe disease in one patient is more likely to cause
severe disease in subsequent patients (6). Considering
these previous study findings, one could hypothesize that
secondary contacts of patients with respiratory manifesta-
tions might be more likely to acquire an infection leading
to severe disease, compared to contacts of patients with
other IGASI manifestations. 
Even though IGASI is a reportable disease, our results
for pneumonia may be an underestimate of the true values.
Given that <1% of community-acquired pneumonia is
attributed to S. pyogenes (34), pneumonia caused by this
bacterium may have been ascribed to other causes and
hence not reported. Our findings are further complicated
by difficulties in defining pneumonia (33). No standard
clinical definition distinguishes IGAS pneumonia from
respiratory distress caused by STSS. Although both clini-
cal manifestations might differ with regard to pathophysi-
ology, given that prophylaxis is required for secondary
contacts of either manifestation in Quebec, difficulties in
distinguishing between these manifestations will probably
not affect the public health implications of our findings. 
With regard to the generalizability of our results, when
comparing our findings with previously published studies,
we did not detect any geographic differences in the inci-
dence of IGASI (17). Our data showed that the yearly inci-
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similar to the incidence of IGASI in British Columbia (20),
Ontario (16), Israel (35), Sweden (19,22), and the United
States (14,18). Furthermore, death rates from IGASI in
Montreal were comparable to death rates calculated for
British Colombia (20) and Sweden (19,22). Only Arizona
appeared to have a higher death rate due to IGASI, at 20%
(3). This difference might be attributable to the elevated
prevalence of diabetes (a risk factor for IGASI) in the
Arizona community studied (3). 
Along with these descriptive findings, we identified sev-
eral factors associated with clinical manifestations of IGAS
and associated death. Having varicella before IGASI
increased the risk of developing a soft-tissue infection 6
times and the risk of dying 5 times. Although we could not
identify any literature linking varicella infection with soft-
tissue infections, given that soft-tissue infections are the
predominant clinical manifestation of IGASI, our findings
support previous research that suggests that varicella might
be an important risk factor for developing IGASI (16,36). 
Soft-tissue infections were almost twice as likely to
develop in persons using drugs. This association could be
attributable to injection drug use; however, it remains even
after controlling for trauma. One explanation for this unex-
pected finding could be nondifferential misclassification.
A subanalysis of drug use showed that 23% of patients
indicated a trauma or wound. However, we were unable to
determine the reliability of reporting. While a patient could
have affirmatively answered to drug use, a wound inflict-
ed by intravenous drug use may not have been considered
sufficiently severe to indicate a trauma or wound. 
Our descriptive analysis appears to support previous
research findings that those <1 year of age and those >60
years of age have the highest incidence of IGASI
(3,21–23). However, previous studies also suggest that
children might have a lower incidence of STSS and be at a
decreased risk of dying of IGASI (21). This research
includes a study that identified a nonsignificant 5-fold rise
in risk for death per year increase in age. In contrast, our
study showed a 2%–4% increase.
Our study finding that M1 and M3 accounted for >30%
of all isolates tested for M surface proteins was consistent
with previous studies that reported these 2 M serotypes as
the most common for IGASI (3,15,16,23,24). This finding
is also consistent with the choice of serotypes to include in
streptococcal vaccines being evaluated at the moment. The
hexavalent vaccine (37) is composed of serotypes 1, 3, 5,
6, 19, and 24; these types represent 38% of isolates in our
study. The types in the 26-valent vaccine (38) represent
70% of our isolates. This number includes M1 with 22%;
M3 with 12%; M28 with 9%; M12 with 8%; M6 with 4%;
M22 and M11 each with 3%; M89 with 2%; and M75, M2,
M77, M43, M5, M76, and M33 each with 1%. 
Furthermore, our study confirmed univariate model
findings from a study by O’Brien et al. that found M3 to be
significantly associated with STSS (14). However, this
association did not remain in our multivariate analysis.
Our findings would thus appear to concur with those of a
another (case-control) study that found while M1 and M3
may be significant risk factors for IGASI, once a person is
infected, environmental and host factors might have a role
in determining the type of invasive disease manifestations
(8,9). This finding could explain why IGASI may develop
in patients infected with the same strain of GAS but have
different clinical manifestations of the disease (e.g., STSS
versus pneumonia) (9). Future epidemiologic studies of
risk factors for clinical manifestations of IGASI might be
designed to look at risk factors separately in patients iden-
tified with M1 and M3 serotypes. By doing so, nondiffer-
ential misclassification might be minimized and risk
factors with weaker associations might be more easily
identified.
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